A Look At Sichuan Kelun-Biotech Biopharmaceutical’s (SEHK:6990) Valuation After Positive 2026 ASCO Lung Cancer Data

Simply Wall St.
Jun 08

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) drew fresh attention after the 2026 ASCO Annual Meeting, where it reported positive Phase III sac-TMT plus pembrolizumab data and pivotal Phase II ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10